GNF179

• CAT Number: I001049
• CAS Number: 1261114-01-5
• Molecular Formula: C22H23ClFN5O
• Molecular Weight: 427.90
• Purity: ≥95%
• Synonyms: 2-amino-1-(3-((4-chlorophenyl)amino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone
• Target: Parasite
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 4.8 nM [1]
• IUPAC Name: 2-amino-1-[3-(4-chloroanilino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7-yl]ethanone
• InChI: InChI=1S/C22H23ClFN5O/c1-22(2)21-27-19(14-3-7-16(24)8-4-14)20(26-17-9-5-15(23)6-10-17)28(21)11-12-29(22)18(30)13-25/h3-10,26H,11-13,25H2,1-2H3
• InChIKey: KFSKTWYDIHJITF-UHFFFAOYSA-N
• SMILES: CC1(C2=NC(=C(N2CCN1C(=O)CN)NC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)F)C

GNF179（Cat No.:I001049）is an optimized 8,8-dimethyl imidazolopiperazine analog exhibiting potent antimalarial activity. It demonstrates an IC₅₀ of 4.8 nM against the multidrug-resistant Plasmodium falciparum strain W2 and is effective in rodent malaria models. GNF179 is orally active and has shown efficacy in reducing parasitemia levels by 99.7% with a single 100 mg/kg oral dose, prolonging mouse survival by an average of 19 days. Its favorable pharmacokinetic profile and metabolic stability make it a promising candidate for further development in malaria treatment.

Reference

[1]. Meister S, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science. 2011 Dec 9;334(6061):1372-7.